Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To compare maternal and newborn outcomes among pregnant women with OUD receiving care via telemedicine versus in-person.
Participants: Pregnant women with OUD.
Intervention: Participants were seen weekly for four weeks, every two weeks for four weeks and monthly thereafter and provided relapse-prevention therapy and buprenorphine.
Design: A cohort derived from a prospectively collected database including 98 women receiving perinatal OUD treatment in an obstetric practice by telemedicine or in-person and followed until 6-8 weeks postpartum from September, 2017 to December, 2018. Logistic regression with propensity score adjustment was applied to reduce group selection bias and control for potentially confounding variables.
Setting: Four outpatient obstetric practices in the southeast.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| In-Person Participants | This group received perinatal OUD treatment in-person. |
| |
| Telemedicine Participants | This group received perinatal OUD treatment via telemedicine. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| In-Person Perinatal OUD Treatment | Behavioral | Participants were seen weekly for four weeks, every two weeks for four weeks and monthly thereafter and provided relapse-prevention therapy and buprenorphine as part of standard of care. |
| Measure | Description | Time Frame |
|---|---|---|
| Number of individuals retained in treatment | Uninterrupted addiction treatment during pregnancy through 6-8 weeks postpartum | 6-8 weeks postpartum |
| Percent of infants born with Neonatal Abstinence Syndrome (NAS) | Newborn withdrawal, also know as NAS gathered via electronic health record | At Delivery |
| Measure | Description | Time Frame |
|---|---|---|
| Positive urine drug screens | Number of individuals with a positive urine drug screen | At delivery and 6-8 weeks postpartum |
| Length of newborn hospital stay and birth weight | Average number of days infant was in the hospital following delivery; weight of infant at birth |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
A cohort derived from a prospectively collected database including 94 women receiving perinatal OUD treatment in an obstetric practice by telemedicine or in-person and followed until 6-8 weeks postpartum from September, 2017 to December, 2018.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The Medical University of South Carolina | Charleston | South Carolina | 29425 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 32003816 | Derived | Guille C, Simpson AN, Douglas E, Boyars L, Cristaldi K, McElligott J, Johnson D, Brady K. Treatment of Opioid Use Disorder in Pregnant Women via Telemedicine: A Nonrandomized Controlled Trial. JAMA Netw Open. 2020 Jan 3;3(1):e1920177. doi: 10.1001/jamanetworkopen.2019.20177. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Perinatal OUD Treatment via Telemedicine | Behavioral | Participants were seen weekly for four weeks, every two weeks for four weeks and monthly thereafter and provided relapse-prevention therapy and buprenorphine as part of standard of care.. |
|
| Assessed up to 6 months following delivery |